PYFAGROUP and XtalPi: Builds a Strategic Partnership as an Initial Step in Accelerating Drug R&D with AI Based Automation and Robotic Technology
From left to right: dr. Widjanarko Brotosaputro – Chief of Strategic Development Officer PYFAGROUP, Yenfrino Gunadi – Chief of Financial Officer PYFAGROUP, Gunawan Lee – Chief of Executive Officer PYFAGROUP, Axel Leven – Director of Strategic Investment and Financing XtalPi
Jakarta, December 12, 2024 – PT Pyridam Farma Tbk (Ticker Code: PYFA), a leading pharmaceutical company in Indonesia, proudly announces its strategic collaboration with XtalPi, a global leader in combining quantum physics, Artificial Intelligence (AI), and robotics to drive innovation in pharmaceutical and new materials.
The collaboration marks a groundbreaking innovation for Indonesia’s pharmaceutical industry. PYFAGROUP is transforming its research and development (R&D) process from labor-intensive methods to a model emphasizing computational and automated workflows. This shift enables faster drug trials with greater data accuracy. This initiative is part of a strategic transformation aimed at conducting faster drug trials without compromising precision and thoroughness. It also enhances PYFAGROUP’s ability to maintain and improve the quality and performance of its pharmaceutical products across various combinations and aspects.
XtalPi will introduce advanced robotic systems and AI-based operations into PYFAGROUP’s drug R&D processes. Rapid R&D data generation will be integrated with hundreds of AI models, enabling faster prediction and validation of new drug candidates, significantly reducing experimental costs and time.
According to Dr. Widjanarko Brotosaputro, Chief of Strategic Development Officer at PYFAGROUP, “Our partnership with XtalPi reflects our commitment to continuously innovate in the development of high-quality medicines. AI-based R&D allows us to predict the safety and efficacy profiles of drugs from the early stages, providing reliable healthcare solutions for the Indonesian population.”
With XtalPi’s proven track record of success, having partnered with global pharmaceutical giants such as Pfizer and Eli Lilly Co., this collaboration marks a pivotal step for PYFAGROUP in strengthening its position in Indonesia’s pharmaceutical industry. PYFAGROUP is ready to revolutionize the drug research and development process, transitioning from labor-intensive methods to AI-powered and automated systems. This transformation will accelerate the development of drug formulations with data-driven accuracy.
“We are thrilled to collaborate with PYFA, bringing our state-of-the-art AI technology to the Indonesian pharmaceutical industry. Our innovative approach, which combines AI, quantum physics, and robotics, has the potential to revolutionize drug development by enhancing efficiency and precision. This partnership marks an exciting new chapter for XtalPi as we expand into this dynamic region.” said Dr. Peiyu Zhang, Chief Scientific Officer at XtalPi.
The collaboration between PYFAGROUP and XtalPi presents significant opportunities for investors through the utilization of advanced technologies in drug development, strengthening PYFAGROUP’s position in the global market, and accelerating the company’s growth. This partnership enhances efficiency in research and development, reduces costs, and shortens product launch timelines, which will positively impact profitability.
Additionally, PYFAGROUP contributes significantly to improving healthcare quality in Indonesia, and this transformation will accelerate the development of drug formulations with data-driven insights. XtalPi’s reputation as a trusted partner and pioneering innovator in AI- powered drug R&D also boosts investor confidence in PYFAGROUP’s strategic vision and competitiveness within the pharmaceutical industry.
About PYFAGROUP
PT Pyridam Farma Tbk, now rebranded as PYFAGROUP, is one of the publicly listed pharmaceutical companies on the Indonesia Stock Exchange (Stock Code: PYFA). PYFAGROUP operates business units producing prescription medicines in various forms, including tablets, capsules, creams, syrups, and injections. PYFAGROUP also has controlled subsidiaries, including PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec Pty Ltd.
Media Relations:
Leilanie Nadia Kusuma
Website: www.pyfa.co.id
Email: corcomm@pyfa.co.id
About XtalPi
XtalPi (XtalPi Holdings Limited, stock code: 2228.HK), is a quantum physics-based, AI-powered, and robotics-driven, innovative R&D platform company. Established in 2015 by three quantum physicists at Massachusetts Institute of Technology (MIT), the company is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions and services for biomedicine, chemical, renewable energy and advanced materials industries globally.
Media Relations:
Website: www.xtalpi.com/en
